

EXHIBIT 1



**JOHNS
HOPKINS**
**Otolaryngology-
Head and Neck Surgery**



Respond to:

818 Ross Research Building
720 Rutland Avenue / Baltimore MD 21205-2196
410-502-5153 / FAX 410-614-1411

Head and Neck Cancer Research Division

David Sidransky, M.D.
Director
dsidrans@jhmi.edu

Edward Ratovitski, Ph.D.
410-502-5130
erat@mail.jhmi.edu

Wayne M. Koch, M.D.
410-955-4906 / FAX 410-955-0035
wkoch@jhmi.edu

Joseph Califano, M.D.
410-502-5153 / 410-955-3155

Barry Trink, Ph.D.
410-502-5153
btrink@jhmi.edu

William H. Westra, M. D.
Pathology
410-955-2163 / FAX 410-955-0115
wwestra@jhmi.edu

Lymari Nieves
Research Coordinator
410-955-3157 / FAX 410-955-0035
410-283-8477 (pager)
lnieves@jhmi.edu

The Editor
Nature Genetics
345 Park Avenue, 10th Floor
New York, New York 10010- 1707

Dear Editor:

Please consider our manuscript entitled, "High frequency of *BRAF* mutation in papillary thyroid carcinoma," For publication in *Nature Genetics* as *Brief Communications*.

On the heels of the identification of the *BRAF* as an important oncogenic protein in melanoma, we have discovered a high frequency of *BRAF* mutations in Papillary thyroid cancer. *BRAF* mutations now represent the most common genetic alteration in these common thyroid neoplasms. Previously, an inverse correlation between ras mutations and *BRAF* mutations were described in a limited number of tumors. We also found an inverse correlation between RASSF1A methylation and *BRAF* mutations in these cancers. Our results thus confirm the importance of map kinase signaling pathway activation in thyroid cancers. We believe that this information will be of great interest to a wide scientific audience.

Thank you as always for reviewing our work.

Sincerely,

David Sidransky, M.D.
Director, Head and Neck Cancer Research
Professor, Otolaryngology - Head and Neck
Surgery, Oncology, Pathology, Urology,
& Cellular and Molecular Medicine